- STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environmentAmbient scribe developer Nabla said Brian Manning will be the Paris-based company's new CEO as it looks to grow in a highly competitive market.STAT · 3d ago↗ source
- Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewIf approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…BioSpace · 3d ago↗ source
- STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.